ArticleCureus2026
Drug-Induced Liver Injury Following Co-ingestion of Veterinary Fenbendazole and Ivermectin for Prostate Cancer: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The self-administration of veterinary-grade anthelmintics, such as fenbendazole and ivermectin, has gained visibility in online communities due to unverified claims regarding potential anticancer effects. Despite these claims, these agents lack human regulatory approval due to unestablished safety profiles. We report a rare case of severe drug-induced liver injury (DILI) in a 65-year-old male with prostate cancer resulting from the concurrent ingestion of veterinary-grade fenbendazole and ivermectin. The patient presented to his primary care provider with a 2-week history of fatigue, jaundice, and abdominal pain following a 3-month regimen of alternating these agents daily at a dosage of "one squirt" (estimated to be 0.18 mg/kg of ivermectin and 0.98 mg/kg of fenbendazole) based on advice from online cancer support groups. Initial laboratory studies revealed profound transaminase elevations, with alanine aminotransferase (ALT) at 1764 U/L, aspartate aminotransferase (AST) at 1132 U/L, and a total bilirubin of 12.9 mg/dL. An R-value of 37.50 confirmed a hepatocellular injury pattern, while an extensive workup ruled out viral, autoimmune, and biliary etiologies. Following the complete cessation of both agents, transaminase levels decreased by 58% within 9 days and normalized within 6 weeks. A Roussel Uclaf Causality Assessment Method (RUCAM) score of 9 indicated a "highly probable" causal relationship between the anthelmintics and the acute liver injury. This case highlights the significant hepatotoxic risks associated with veterinary-grade therapies driven by medical misinformation. Overall, this case emphasizes the need for physicians to maintain a high index of suspicion for alternative therapies in oncology patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.